Your fat can save your lifeback to overview
Leuven based TiGenix NV (TIG), leading European cell therapy company, was recently granted an European Patent for using patient’s own fatty cells (adipocytes) to generate the stem cells for the treatment of inflammatory and autoimmune diseases.
TiGenix constantly broadens their horizons and the spectrum of the offered therapies. Their first commercial product, ChondroCelect®, for cartilage repair in the knee, was Europe’s first approved cell-based product. This year the company decided to reach to the global market by teaming up with Lonza, a world leader in biological and cell therapy manufacturing. Lonza will produce the therapeutic (Cx601) for Crohn’s disease symptoms for Phase 3 clinical trial in the US. Crohn’s disease affects between 30,000 and 50,000 patients in Europe and about 700,000 in America. Another therapeutic candidate in the TiGenix’s pipeline (Cx611) is being tested for early rheumatoid arthritis and for severe sepsis.